These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 3978829)

  • 1. Bioactive forms of serum lactogens: effects of treatment of prolactinoma patients with bromocriptine.
    Rennie PS; Prior JC; Bruchovsky N; Gout PW
    Clin Endocrinol (Oxf); 1985 Jan; 22(1):65-73. PubMed ID: 3978829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of a long-acting injectable form of bromocriptine in patients with prolactin and growth hormone secreting macroadenomas.
    Tsagarakis S; Tsiganou E; Tzavara I; Nikolou H; Thalassinos N
    Clin Endocrinol (Oxf); 1995 Jun; 42(6):593-9. PubMed ID: 7634499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperprolactinemic response after bromocriptine withdrawal in women with prolactin-secreting pituitary tumors.
    Maxson WS; Dudzinski M; Handwerger SH; Hammond CB
    Fertil Steril; 1984 Feb; 41(2):218-23. PubMed ID: 6698215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of big, big prolactin in patients with hyperprolactinaemia.
    Leite V; Cosby H; Sobrinho LG; Fresnoza MA; Santos MA; Friesen HG
    Clin Endocrinol (Oxf); 1992 Oct; 37(4):365-72. PubMed ID: 1483294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bromocriptine treatment of prolactin-secreting pituitary adenomas may restore pituitary function.
    Warfield A; Finkel DM; Schatz NJ; Savino PJ; Snyder PJ
    Ann Intern Med; 1984 Dec; 101(6):783-5. PubMed ID: 6497193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secretion of glycoprotein hormone alpha-subunit by pituitary tumors.
    Ishibashi M; Yamaji T; Takaku F; Teramoto A; Fukushima T
    J Clin Endocrinol Metab; 1987 Jun; 64(6):1187-93. PubMed ID: 2437140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parenteral bromocriptine in the treatment of hormonally active pituitary tumours.
    Benker G; Gieshoff B; Freundlieb O; Windeck R; Schulte HM; Lancranjan I; Reinwein D
    Clin Endocrinol (Oxf); 1986 May; 24(5):505-13. PubMed ID: 3791649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA synthesis by pituitary tumours, with reference to plasma hormone levels and to effects of bromocriptine.
    Lloyd HM; Jacobi JM; Willgoss DA
    Clin Endocrinol (Oxf); 1995 Jul; 43(1):79-85. PubMed ID: 7641414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and morphological findings in two cases of bromocriptine-treated prolactinomas.
    Anniko M; Wersäll J
    Acta Pathol Microbiol Scand A; 1981 Jan; 89(1):41-7. PubMed ID: 7223426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Demonstration of biological activity of prolactin molecular weight variants in human sera.
    Whitaker MD; Klee GG; Kao PC; Randall RV; Heser DW
    J Clin Endocrinol Metab; 1984 May; 58(5):826-30. PubMed ID: 6707188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The presence of macromolecular prolactin in serum of pregnant women and patients with pituitary adenoma.
    Ohnami S; Eto S
    J UOEH; 1985 Jun; 7(2):185-92. PubMed ID: 4023466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of new homologous in vitro bioassays for human lactogens to assess the actual bioactivity of human prolactin isoforms in hyperprolactinaemic patients.
    Leaños-Miranda A; Cárdenas-Mondragón G; Rivera-Leaños R; Ulloa-Aguirre A; Goffin V
    Clin Endocrinol (Oxf); 2006 Aug; 65(2):146-53. PubMed ID: 16886952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance to bromocriptine in prolactinomas.
    Pellegrini I; Rasolonjanahary R; Gunz G; Bertrand P; Delivet S; Jedynak CP; Kordon C; Peillon F; Jaquet P; Enjalbert A
    J Clin Endocrinol Metab; 1989 Sep; 69(3):500-9. PubMed ID: 2760167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum prolactin and growth hormone determined by radioimmunoassay and a two-site immunoradiometric assay: comparison with the Nb2 cell bioassay.
    Rose DP; Berke B; Cohen LA
    Horm Metab Res; 1988 Jan; 20(1):49-53. PubMed ID: 3371857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of action and tolerance of mesulergine.
    Lamberts SW; Klÿn JG; Oosterom R
    Clin Pharmacol Ther; 1984 Nov; 36(5):620-7. PubMed ID: 6488683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pulsatile thyrotropin and prolactin secretion in a patient with a mixed thyrotropin- and prolactin-secreting pituitary adenoma.
    Adriaanse R; Brabant G; Endert E; Bemelman FJ; Wiersinga WM
    Eur J Endocrinol; 1994 Feb; 130(2):113-20. PubMed ID: 8130883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perifusion studies of bromocriptine-treated and untreated macroprolactinomas: effects of dopamine, bromocriptine and TRH.
    Bevan JS; Burke CW
    Clin Endocrinol (Oxf); 1989 Jun; 30(6):667-80. PubMed ID: 2512041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spontaneous sparsely-granulated prolactin-producing pituitary adenomas in aging rats. A prospective study of the effect of bromocriptine.
    McComb DJ; Hellmann P; Kovacs K; Scott D; Evans WS; Burdman JA; Thorner MO
    Neuroendocrinology; 1985 Sep; 41(3):201-11. PubMed ID: 4047338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of tamoxifen administration on prolactin release by invasive prolactin-secreting pituitary adenomas.
    Lamberts SW; Verleun T; Oosterom R
    Neuroendocrinology; 1982; 34(5):339-42. PubMed ID: 7078703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bromocriptine treatment of women with suspected pituitary prolactin-secreting microadenomas.
    Archer DF; Lattanzi DR; Moore EE; Harger JH; Herbert DL
    Am J Obstet Gynecol; 1982 Jul; 143(6):620-5. PubMed ID: 7201244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.